Wat is de prijs voor GenSight Biologics S.A. (SIGHT)

Het prijs van GenSight Biologics S.A. (SIGHT) is $0.12098783

Wat is de marktkapitalisatie voor GenSight Biologics S.A. (SIGHT)

Marktkapitalisatie voorGenSight Biologics S.A. (SIGHT) is $19.72M

GenSight Biologics S.A. (SIGHT) Prijs en Marktkapitalisatie

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Prijs voor SIGHT	Aandeel B	Marktkapitalisatie van B	uitslagen
$32,555.70 $19.72M	NVDA	$5.307T	+26,908,142.59%
$27,918.59 $19.72M	AAPL	$4.551T	+23,075,437.31%
$25,486.88 $19.72M	GOOG	$4.154T	+21,065,559.84%
$22,015.62 $19.72M	MSFT	$3.589T	+18,196,455.21%
$17,158.56 $19.72M	AMZN	$2.797T	+14,181,958.43%

Prijs voor SIGHT

Aandeel B

Marktkapitalisatie van B

uitslagen

$32,555.70 $19.72M